These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 7374415

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
    Kaffarnik H, Schneider J, Schubotz R, Zöfel P, Hausmann L, Goebel KM.
    Artery; 1980; 8(6):537-46. PubMed ID: 6114725
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [The effect of etofibrate on serum cholesterol and triglycerides (author's transl)].
    Dimroth H.
    Med Klin; 1979 Jun 01; 74(22):875-6. PubMed ID: 470785
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 Jun 01; 33(5):776-9. PubMed ID: 6683558
    [Abstract] [Full Text] [Related]

  • 9. [Clofibrate therapy--the status quo].
    Reuter W.
    Z Gesamte Inn Med; 1982 Jan 15; 37(2):59-63. PubMed ID: 7080553
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
    Sirtori M, Montanari G, Gianfranceschi G, Malacrida MG, Battistin P, Morazzoni G, Tremoli E, Colli S, Maderna P, Sirtori CR.
    Atherosclerosis; 1983 Nov 15; 49(2):149-61. PubMed ID: 6365105
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Possible glucagon-mediated hypocholesterolemic activity of a nicotinic acid derivative (sorbinicate).
    Uccella R, Morenghi R, Agosti C, Saponati G.
    Artery; 1983 Nov 15; 11(5):400-12. PubMed ID: 6661043
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Atherosclerosis treatment with etofibrate retard. New perspectives].
    Degenring FH, Schatton W, Hotz W.
    Fortschr Med; 1983 Aug 11; 101(30):1391-6. PubMed ID: 6618402
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia].
    Schwartzkopff W, Schilling A.
    Med Welt; 1980 Dec 12; 31(50):1845-50. PubMed ID: 7464535
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.